• Explore /
  • Poster
  • / Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).

Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).

Abstract Poster

Authors

null

Michel Delforge

University of Leuven, Leuven, Belgium

Michel Delforge , Krina K. Patel , Laurie Eliason , Devender Dhanda , Ling Shi , Shien Guo , Thomas Marshall , Bertrand Arnulf , Michele Cavo , Ajay K. Nooka , Salomon Manier , Natalie Scott Callander , Sergio Giralt , Hermann Einsele , Sikander Ailawadhi , Mihaela Popa McKiver , Mark Cook , Paula Rodríguez-Otero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT03651128

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8032)

DOI

10.1200/JCO.2023.41.16_suppl.8032

Abstract #

8032

Poster Bd #

24

Abstract Disclosures

Similar Posters

First Author: Richard S. Finn

First Author: Richard S. Finn

First Author: Thomas G. Martin

First Author: Evangelos Terpos